NCT06723392 Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
| NCT ID | NCT06723392 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | NICHD Global Network for Women's and Children's Health |
| Condition | Preterm Birth |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,134 participants |
| Start Date | 2025-12-08 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 1,134 participants in total. It began in 2025-12-08 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study, Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries (ABLE), is designed as a 2-arm randomized controlled trial (RCT) focused on pregnant individuals and newborn infants. A positive outcome of this study will contribute to global progress toward WHO Sustainable Development Goal Target 3.2 \[End preventable deaths of newborns and children under 5 years of age\] by examining the potential impact of this practice to reduce the incidence of SVN/SB and the lifelong health consequences associated with SVNs. In addition, the study will further explore the role and potential benefits of antibiotic treatment of AB in the pregnant individual. In total, 1,134 eligible participants, or approximately 162 per research site, will be randomized in the trial by the research teams in each of the seven international sites that, together with their United States of America (US) partners, participate in the Eunice Kennedy Shriver National Institute of Child Health and Human Development's (NICHD's) Global Network for Women's and Children's Health Research (GN).
Eligibility Criteria
Inclusion Criteria: Individuals who meet the following criteria are eligible for randomization: * Enrolled in GN MNHR * Established pregnancy ≥12 and ≤20 weeks GA by last menstrual period and/or clinical assessment and/or ultrasonography * Age: 18 years (or lower limit age eligible\*) to 49 years \* Some sites will be able to include individuals giving birth regardless of age if they are considered an adult or an emancipated minor. However, other sites will require individuals to be at least 18 years of age. The investigators will adhere to local regulations. * Expressed understanding of study procedures and willingness to complete screening, randomization, study drug administration and follow-up * Able to provide informed consent * Presence of a single bacterial isolate (\>105 colony forming unit (CFU)/mL) in urine at enrollment * Intent to remain in study area for at least 42 days PP Exclusion Criteria: Individuals who meet any of the following criteria are not eligible for randomization: * Gestational age \<12 weeks or \>20 weeks * Received treatment with any antibiotic within 14 days before screening visit * Current symptoms of UTI * History of allergy to nitrofurantoin * Pregnancy loss / miscarriage prior to randomization * Currently taking magnesium-containing antacid * Any illness / condition (e.g., anemia, diabetes, renal disease, pulmonary disease) requiring immediate medical care per site PI assessment * Enrollment in another trial that per the study MOP will impact this trial
Frequently Asked Questions
Who can join the NCT06723392 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 49 Years, studying Preterm Birth. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06723392 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 1,134 participants.
Is NCT06723392 currently recruiting?
Yes, NCT06723392 is actively recruiting participants. Visit ClinicalTrials.gov or contact NICHD Global Network for Women's and Children's Health to inquire about joining.
Where is the NCT06723392 trial being conducted?
This trial is being conducted at Dhaka, Bangladesh, Kinshasa, Democratic Republic of the Congo, Guatemala City, Guatemala, Belagavi, India and 3 additional locations.
Who is sponsoring the NCT06723392 clinical trial?
NCT06723392 is sponsored by NICHD Global Network for Women's and Children's Health. The trial plans to enroll 1,134 participants.